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OBJECTIVE — To investigate the relationship among A1C, fasting plasma glucose (FPG),
and 2-h postload plasma glucose in the Dutch general population and to evaluate the results of
using A1C for screening and diagnosis of diabetes.
RESEARCH DESIGN AND METHODS — In 2006–2007, 2,753 participants of the
New Hoorn Study, aged 40–65 years, who were randomly selected from the population of
Hoorn, the Netherlands, underwent an oral glucose tolerance test (OGTT). Glucose status
(normal glucose metabolism [NGM], intermediate hyperglycemia, newly diagnosed diabetes,
and known diabetes) was deﬁned by the 2006 World Health Organization criteria. Spearman
correlations were used to investigate the agreement between markers of hyperglycemia, and a
receiver operating characteristic (ROC) curve was calculated to evaluate the use of A1C to
identify newly diagnosed diabetes.
RESULTS — In the total population, the correlations between fasting plasma glucose and
A1C and between 2-h postload plasma glucose and A1C were 0.46 and 0.33, respectively.
In patients with known diabetes, these correlations were 0.71 and 0.79. An A1C level of
5.8%, representing 12% of the population, had the highest combination of sensitivity
(72%) and speciﬁcity (91%) for identifying newly diagnosed diabetes. This cutoff point
would identify 72% of the patients with newly diagnosed diabetes and include 30% of the
individuals with intermediate hyperglycemia.
CONCLUSIONS — Inpatientswithknowndiabetes,correlationsbetweenglucoseandA1C
are strong; however, moderate correlations were found in the general population. In addition,
based on the diagnostic properties of A1C deﬁned by ROC curve analysis, the advantage of A1C
compared with OGTT for the diagnosis of diabetes is limited.
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F
astingglucoselevelsandglucoselev-
els 2 h after a glucose tolerance test
(postloadglucoselevels)areusedfor
diagnosis and management of diabetes
(1). In addition, the A1C level is used to
monitor glycemia in patients with diabe-
tes because it has less day-to-day variabil-
ity than glucose levels and is thought to
reﬂect chronic glycemia (2).
In 2007, a consensus statement re-
ported on the worldwide standardization
of the A1C measurement (3). One of the
conclusions was that glycemic goals in
clinical practice should be expressed in
three types of units, one of which is the
International Federation of Clinical
ChemistryandLaboratoryMedicinestan-
dardized method. Use of this method im-
pliesthattheunitofmeasurementofA1C
will change from a percentage to milli-
moles per mole. The introduction of this
new unit of measurement may be confus-
ing for patients and health care providers.
Therefore,theA1C-DerivedAverageGlu-
cose (ADAG) Study Group investigated
whether A1C can be translated into aver-
age blood glucose levels in patients with
diabetes (4). A major advantage of using
the average glucose level for chronic gly-
cemia is that it has the same unit of mea-
surement (millimoles per liter) as that for
acute glycemia. The ADAG Study Group
concluded that the average glucose level
was strongly correlated with A1C and
that the translation of A1C into average
glucose levels was therefore possible
(4). Moreover, Saudek et al. (5) recom-
mended 1) the use of an A1C level of
6.0%asascreeningstandardforthede-
tection of individuals at high risk of de-
veloping diabetes, 2) an A1C level of
6.5% conﬁrmed by a glucose test (fast-
ingororalglucosetolerancetest[OGTT])
for the diagnosis of diabetes, and 3) A1C
levels of 7.0% measured twice or con-
ﬁrmed by a glucose test for the diagnosis
of diabetes. During the review process for
the present article, a consensus statement
from an International Expert Committee
that recommended the use of A1C levels
6.5% for the diagnosis of diabetes in-
stead of glucose measures was published.
A1C levels between 6.0 and 6.5% are pro-
posed to identify individuals at high risk of
developing diabetes (6). It may, however,
be questioned whether A1C is a good indi-
cator of glucose in individuals with normal
or moderately elevated glucose levels and
whether it can therefore be used to identify
those with intermediate hyperglycemia or
undiagnosed diabetes. Therefore, our aim
was to investigate the relationship between
glucose and A1C in the general population
and to evaluate the use of A1C for the
screening and diagnosis of diabetes.
RESEARCH DESIGN AND
METHODS— From July 2006 to No-
vember 2007, a population-based study
onglucosetolerancewasperformedinthe
city of Hoorn, the Netherlands (the New
Hoorn Study). A random sample of 6,180
men and women aged 40–65 years was
drawn from the municipal population
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vacy legislation, all potential participants
received a letter on behalf of the munici-
pality,withadescriptionofthestudy,and
the request to return a form with their
name, address, and telephone number.
When the form was not returned within
2 weeks, a reminder was sent. To in-
crease the participation rate, a local
media campaign was started, and par-
ticipants had the ability to visit the Di-
abetes Research Center on Saturdays.
The study was approved by the medical
ethics committee of the VU University
Medical Center Amsterdam.
Data collection
Before their visit, participants received a
questionnaire containing information on
demographics, lifestyle, medication, and
(family) history of disease. Participants
were requested to refrain from eating and
drinking(exceptwater)from8:00 P.M.the
night before the visit and from drinking
alcohol from 5:00 P.M. the day before the
visit. They were instructed to follow their
usual diet the day before each visit and to
beconsistentintheirdiet(bothincontent
and in approximate timing of evening
meals and snacks) and physical activities
on the previsit days. In addition, partici-
pants were requested not to smoke on the
morning of the visit and not to come by
bicycle. Participants who had not been
followingtheseinstructionswereaskedto
reschedule the visit. Upon arrival at the
Diabetes Research Center, written in-
formed consent was obtained.
Height and weight were measured
withoutshoesandheavyclothes.BMIwas
calculated as weight in kilograms divided
by the square of height in meters. The
waist circumference was measured be-
tween the lower rib margin and the spina
iliaca anterior superior, and the hip cir-
cumference was measured over the max-
imum of the buttocks. The waist-to-hip
ratio (waist circumference divided by hip
circumference) was calculated. Blood
pressurewasmeasuredthreetimesonthe
rightarmaftera10-minrestperiod,using
a Colin Press Mate BP 8800p noninvasive
blood pressure monitor (Colin Medical
Technology). Final blood pressure was
calculated as the mean of the last two
measurements. Fasting whole blood glu-
cosefromacapillaryveinintheﬁngerwas
determinedonthespotusingaHemoCue
-glucose analyzer. In participants with a
fasting whole blood glucose level 10
mmol/l, a standard 75-g OGTT was per-
formed. Venous blood samples were
drawn before and 120 min after glucose
ingestion.
Laboratory assays
All analyses were performed at the clinical
chemistry laboratory of the VU University
Medical Center Amsterdam. Glucose was
measured in venous plasma by the glucose
oxidase method (Gluco-quant/hexokinase/
G6P-DH; Boehringer-Mannheim, Mann-
heim, Germany). A1C was assessed using
Diabetes Control and Complications Trial
(DCCT) standardized reverse-phase cation
exchange chromatography (HA 8160 ana-
lyzer; Menarini, Florence, Italy) The intra-
assaycoefﬁcientofvariationwas0.65%ata
mean of 4.89%, and the interassay coefﬁ-
cient of variation was 1.55% at a mean of
5.52%. Triglycerides, total cholesterol, and
HDL cholesterol were determined from
fasting plasma samples by enzymatic tech-
niques (Boehringer-Mannheim). LDL cho-
lesterol was estimated with the Friedewald
formula, except in individuals with triglyc-
erides 4.5 mmol/l.
Statistical analyses
Based on the results of the OGTT, partici-
pants were categorized into three groups
using the 2006 World Health Organization
criteria (1): normal glucose metabolism
(NGM), intermediate hyperglycemia, or
newly detected diabetes. In addition,
known diabetes was deﬁned by the use of
insulin or oral hypoglycemic agents and
self-reported known diabetes. Differences
betweenthesubgroupsofglucosetolerance
were tested using one-way ANOVA.
Scatter plots with estimated linear or
curvilinear relationships were plotted to
describetherelationbetweenglucoseand
A1C in the total population. In addition,
the correlations among A1C, fasting
plasma glucose (FPG), and 2-h postload
plasma glucose were determined using
Spearman correlations. After exclusion of
participants with known diabetes, the di-
agnosticpropertyofA1Cforthediagnosis
of diabetes was evaluated by calculating a
receiver operating characteristic (ROC)
curve. The area under the ROC curve
(AUC) with 95% CI was calculated. To
describe the effect of different cutoff
points of A1C, sensitivity and speciﬁcity
were used. In addition, the positive pre-
dictive value (PPV) and negative predic-
tive value (NPV) for every cutoff point
were calculated. All analyses were per-
formed using the Statistical Package for
the Social Sciences (SPSS for Windows
15.0). The P value for statistical signiﬁ-
cance was set at 0.05.
RESULTS
Population characteristics
Of the 6,180 people who were invited,
2,807 agreed to participate (45.4%). Of
the nonattendees, 47% provided a reason
for not participating, of which the most
common were no time to participate
(43%) and already having regular health
checks (24.5%). After exclusion of 54
participants with missing glucose values,
2,753 participants were included for
the analysis. Table 1 presents the popula-
tion characteristics in subgroups with
different glucose tolerance status. The
prevalences of NGM, intermediate hyper-
glycemia, newly diagnosed diabetes, and
known diabetes were 77, 16, 4, and 3%,
respectively. Compared with the other
categories, participants with known dia-
betes were more often male, were older,
andhadhighermeanbloodglucose,A1C,
BMI, and waist-to-hip ratio. Their blood
pressure and lipid levels were lower than
those in patients with newly diagnosed
diabetes, probably because of the treat-
ment regimen for diabetic patients used
by general practitioners in the Nether-
lands (7).
Correlations among A1C, FPG, and
2-h postload plasma glucose
Figure 1 presents the scatter plots for the
association between FPG and A1C and
between2-hpostloadplasmaglucoseand
A1C. Using a linear association model, R
2
values, a measure of explained variance,
were 0.57 for the association between
FPGandA1Cand0.35fortheassociation
between2-hpostloadplasmaglucoseand
A1C (both P  0.01). Use of exponential
or quadratic models did not improve the
ﬁt of the model (data not shown) nor
could a threshold be identiﬁed. In Table
1,theSpearmancorrelationsamongA1C,
FPG,and2-hpostloadplasmaglucoseare
presented. In the total population, the
correlations between A1C and FPG were
strongerthanthosebetweenA1Cand2-h
postload plasma glucose (0.46 and 0.33,
respectively). Because earlier research
provided correlations in subgroups of
glucose tolerance status, we also provide
correlations within these subgroups (Ta-
ble 1, bottom rows). Correlations be-
tweenA1Candglucoseinsubgroupswith
NGM, intermediate hyperglycemia, and
newly diagnosed diabetes ranged be-
tween 0.050 and 0.53. In patients with
known diabetes, the correlations were
stronger and reached levels between 0.71
and 0.79.
A1C and glucose in general Dutch population
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Figure 2 shows the results of the analyses
of A1C as a possible tool for the screening
anddiagnosisofdiabetes,basedonaROC
curve. The AUC was 0.895 (95% CI
0.861–0.930). In Table 2, the diagnostic
properties of different A1C cutoff points
are described. The cutoff point for identi-
fying newly diagnosed diabetes with the
highest sum of sensitivity (72%) and
speciﬁcity (91%) was an A1C level of
5.8%.OfallindividualswithanA1Clevel
5.8%, 24% had diabetic glucose levels.
When the recently proposed cutoff point
of 6.0% for the screening of individuals at
high-risk of diabetes (5,6) was used, the
sensitivity and speciﬁcity were 56 and
97%, respectively. Less than half of the
individuals with A1C levels 6.0% had
diabetic glucose levels (PPV of 42%) and
15%oftheparticipantswithintermediate
hyperglycemia had A1C levels 6.0%.
For the diagnosis of diabetes, A1C levels
6.5 and 7.0% were proposed (5,6). Of
the participants with A1C 6.5 and
7.0%, 93 and 100% had diabetic glucose
levels, respectively. However, of all pa-
Table 1—Population characteristics and Spearman correlations between markers of hyperglycemia in the total population and in participants
with normal glucose tolerance, intermediate hyperglycemia, newly diagnosed diabetes, or known diabetes
Total
population NGM IH NDM KDM
n (%) 2,753 2,122 (77) 439 (16) 107 (4) 85 (3)
Male sex (%) 46.9 44.2 56.4* 47.2 64.6*‡
Age (years) 53.5  6.7 52.8  6.8 55.2  6.2* 55.8  6.3* 56.9  6.0*
Not of Dutch origin (%) 10.8 9.8 13.2* 17.6* 13.9
Diabetes duration (years) — — — — 7.3 (8.14)
Systolic blood pressure (mmHg) 133.3  18.1 130.8  17.4 140.9  18.2* 146  20.5*† 138.6  17.2*‡
Diastolic blood pressure (mmHg) 76.6  10.6 75.5  10.4 80.2  10.4* 82.6  10.5* 78.5  9.2 ‡
Weight (kg) 79.0  14.6 77.2  13.5 84.1  15.9* 86.1  15.4* 91.0  17.2*†
BMI (kg/m
2) 26.3  4.0 25.6  3.7 27.9  4.2* 28.8  4.3* 30.0  5.1*†
Waist (cm) 89.8  11.8 87.7  10.7 95.3  11.7* 99.1  11.7*† 103.1  15.5*†
Waist-to-hip ratio 0.89  0.08 0.88  0.08 0.93  0.08* 0.95  0.07* 0.97  0.07*†
Total cholesterol (mmol/l) 5.5  1.0 5.4  0.96 5.7  1.07 5.7  1.08 5.0  1.41*†‡
HDL cholesterol (mmol/l) 1.51  0.42 1.56  0.42 1.38  0.39* 1.28  0.38* 1.29  0.38*
Triglycerides (mmol/l)§ 1.2 (0.9–1.7) 1.1 (0.8–1.6) 1.6 (1.2–2.2)* 2.0 (1.4–2.7)*† 1.7 (1.1–2.6)*
FPG (mmol/l) 5.6  0.95 5.30  0.38 6.0  0.51* 7.7  2.24*† 7.9  2.12*†
2-h postload plasma glucose (mmol/l) 5.9  2.4 5.09  1.13 7.5  1.78* 11.50  3.24*† 13.2  5.07*†‡
A1C (%) 5.5  0.52 5.3  0.26 5.6  0.33* 6.4  1.25*† 6.7  1.16*†‡
A1C vs. fasting plasma glucose  0.46¶ 0.26¶ 0.25¶ 0.53¶ 0.71¶
A1C vs. 2-h postload plasma glucose  0.33¶ 0.14¶ 0.050 0.43¶ 0.79¶
FPG vs. 2-h postload plasma glucose  0.40¶ 0.20¶ 0.50¶ 0.13 0.66¶
Values are means  SD, percentage, or median (25th–75th percentile). *Signiﬁcantly different from normal glucose tolerance. †Signiﬁcantly different from
intermediate hyperglycemia. ‡Signiﬁcantly different from newly diagnosed diabetes. §Log-transformed before testing. Spearman correlations. ¶Statistically signif-
icant (P  0.05) correlation. IH, intermediate hyperglycemia; NDM, newly diagnosed diabetes; KDM, known diabetes.
Figure 1—Scatter plots of FPG and 2-h postload plasma glucose in relation to A1C in the total population. Diabetic patients are indicated by dotted
reference lines at FPG levels of 7.0 mmol/l and 2-h postload plasma glucose levels of 11.1 mmol/l.
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6.5 and 12% had A1C levels 7.0%.
In clinical care, FPG instead of an
OGTT is mostly used to diagnose diabe-
tes. To compare the diagnostic properties
of A1C with FPG, we performed similar
ROC curve analyses for FPG and for A1C,
usingOGTTasthecriterion.TheAUCfor
FPG was 0.937 (95% CI 0.905–0.969)
(data not shown).
CONCLUSIONS— In the general
Dutch population, the correlations be-
tween glucose (fasting and postload) and
A1C were moderate compared with these
correlations in patients with known dia-
betes. In addition, when one is using A1C
levels 6.0% to screen for diabetes in the
general population, almost half of the
people with diabetic glucose levels would
be missed. Last, the A1C cutoff point of
7.0% has a speciﬁcity of 100% and is
present among 12% of patients with
newly diagnosed diabetes.
Nathan et al. (4) reported recently
that A1C and average glucose levels mea-
sured during the day were highly associ-
ated in a population of mainly type 1
diabetic patients. This observation is con-
sistent with our ﬁndings in patients with
diagnosed type 2 diabetes and earlier re-
search (8). Our research, however, shows
that the correlations between glucose and
A1C were moderate in a random sample
of the general population.
The cutoff point for screening for di-
abetes with the highest sum of sensitivity
and speciﬁcity in our data was an A1C
level of 5.8%. This cutoff point would de-
tect 72% of patients with newly diag-
nosed diabetes and 30% of individuals
at high risk of developing diabetes (par-
ticipants with intermediate hyperglyce-
mia). Use of A1C levels of 6.0% for the
screening of individuals at high risk of
developing diabetes would lead to identi-
fying 15% of the individuals with inter-
mediate hyperglycemia. Moreover, 44%
ofpatientswithnewlydiagnoseddiabetes
had A1C levels 6.0%. This observation
is consistent with ﬁndings in the National
HealthandNutritionExaminationSurvey
(NHANES), in which an A1C level of
5.8% was also found to have the highest
sum of sensitivity and speciﬁcity (9,10)
and in which 60% of patients with newly
diagnosed diabetes had A1C levels
6.1% (11).
BecauseallparticipantswithA1Clev-
els 7.0% had diabetic glucose levels,
our data conﬁrm that A1C levels of
7.0% can be used as a threshold not
requiring further glucose testing for the
diagnosis of diabetes. A limitation of this
diagnostic criterion is the low sensitivity
as shown in our study as well as in the
NHANES studies (9,10). Therefore, in
most of individuals, an OGTT would still
be necessary to verify the diagnosis.
Moreover, our data showed that FPG had
a higher area under the ROC curve than
A1C, indicating a higher diagnostic value
of FPG than A1C for identifying newly
diagnosed diabetes. The conclusion in
other population-based research was that
A1C had no additional diagnostic value
comparedwithfastingglucosealone(12),
except in high-risk groups (13). Despite
thecurrentlydiscussedlimitationsofA1C
for the diagnosis of diabetes compared
withanOGTT,A1Cmaybesuperiorthan
OGTT in terms of cost-effectiveness and
practical use in the clinical setting, be-
Figure 2—ROC curve for identiﬁcation of participants with previously undiagnosed diabetes,
usingA1CfordiagnosisandanOGTTascriterion.A1Ccutoffpointsof5.8,6.0,6.5,and7.0%are
indicated on the curve.
Table 2—Sensitivity, speciﬁcity, PPV, and NPV for diabetes using different A1C cutoff points
A1C
% total
population
% high
risk (IH)
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
5.5% 41 70 91 61 9 99
5.6% 28 57 86 74 12 99
5.7% 19 42 78 83 16 99
5.8% 12 30 72 91 24 99
5.9% 8 21 67 94 33 98
6.0% 5 15 56 97 42 98
6.1% 4 9 42 98 54 98
6.5% 1 1 24 99 93 97
7.0% 1 0 12 100 100 95
IH, intermediate hyperglycemia.
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and measurement of A1C is less time-
consuming than an OGTT. Moreover,
A1C might be a good indicator for future
complications. Large-scale epidemiologi-
cal studies have shown that A1C level is
associated with complications such as
cardiovasculardisease,eveninthenondi-
abetic range of glucose tolerance (14,15).
The moderate correlations of glucose
with A1C found in this study may imply
thatA1Candglucosereﬂectdifferentpro-
cesses,especiallyinthenondiabeticrange
of glucose tolerance. The amount of gly-
cosylationisknowntovaryinterindividu-
ally (16,17). Possible mechanisms are
genetic traits (18), aging (19), differences
in erythrocyte environments (20), heter-
ogeneity in red-cell lifespan (21), and ra-
cial differences (22). In participants with
knowndiabetes,thecorrelationsbetween
glucoseandA1Cwerestrongerthanthose
in participants with newly diagnosed dia-
betes. It can be speculated that longer di-
abetes duration is accompanied by
changes in the intraerythrocyte environ-
ment. Another explanation may be the
degree of glycemic control. Kilpatrick et
al. (23) showed in the DCCT that for any
given A1C, the plasma glucose levels of
participants in different treatment groups
were not the same.
TheNewHoornStudyisapopulation
study of individuals who were randomly
selected. Therefore, we had the ability to
study the relation between A1C and glu-
cose in a representative sample of the
Dutch population with different stadia of
glucose tolerance. A limitation of the
present study was that only 45.4% of the
originallyinvitedsampleagreedtopartic-
ipate. As a result, we cannot exclude the
possibility that self-selection occurred,
possibly leading to overrepresentation of
individuals with an interest in diabetes.
Second,wedidnothavetheavailabilityof
continuous glucose monitoring during
the day and only one OGTT was per-
formed on all participants. It can be sug-
gested that the moderate correlations
between glucose and A1C in the present
studyareduetotheratherhighvariability
of FPG and 2-h postload plasma glucose
within individuals (24). However, de
Vegtetal.(25)showedthatthisvariability
did not result in a different reproducibil-
ity for the categorization of glucose toler-
ance over 6 years. In addition, the
correlations between glucose and A1C in
patients with known diabetes found in
our study are comparable to the correla-
tions found in the study by Nathan et al.
(4), in which continuous glucose moni-
toring was used in patients with known
diabetes. Correlation coefﬁcients are sen-
sitive for the differences in ranges of the
variablesincludedandtendtobelowerin
subgroups with a smaller range. The
range of glucose and A1C is large in pa-
tients with diabetes, resulting in strong
correlations. However, in our study the
correlationsbetweenglucoseandA1Cwere
stronger in participants with diabetes than
in the total population, whereas the ranges
of both glucose and A1C are larger in the
total population. These ﬁndings indicate
that differences in ranges are not the only
explanation of the differences found in the
correlationsamongthetotalpopulationand
subpopulations with diabetes.
To summarize, our results support
the ongoing research on the translation of
A1C into A1C-derived glucose in people
with known diabetes. However, based on
the moderate correlations between glu-
cose and A1C in the total sample, transla-
tion of A1C into average glucose in the
general population is not recommended.
Moreover, based on diagnostic properties
only, the advantage of using A1C instead
of an OGTT for both screening and diag-
nosis of diabetes is limited, and glucose
measures will still be necessary in most
patients to verify the outcome. However,
research including cost-effectiveness,
practical use, and the role of A1C in the
development of future complications is
neededtofurtherexplorethisconclusion.
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